Tumor Necrosis Factor Inhibitors
Finding culprit drug challenging in Stevens-Johnson syndrome/toxic epidermal necrolysis
Physicians must change their approaches to finding culprit drugs when treating Stevens-Johnson syndrome/toxic epidermal necrolysis, according to a study.
Ozoralizumab exhibits long half-life, favorable pharmokinetics in rheumatoid arthritis
Ozoralizumab demonstrates a long half-life and favorable pharmacokinetics, as well as sustained efficacy, over 52 weeks in patients with rheumatoid arthritis, according to data published in Arthritis Research & Therapy.
Biologic DMARDs control ICI-associated inflammatory arthritis quicker than methotrexate
Patients with immune checkpoint inhibitor-associated inflammatory arthritis who receive a biologic DMARD demonstrate quicker arthritis control, but also experience faster cancer progression, vs. methotrexate, according to data.
Lack of ‘good disease model’ inhibits treatment decision-making in axial spondyloarthritis
DESTIN, Fla. — Incomplete understanding of axial spondyloarthritis disease process poses challenges for treatment decision making, according to a presenter at the 2023 Congress of Clinical Rheumatology-East.
Benefits outweigh risks when switching biologics for rheumatoid arthritis
Patients with rheumatoid arthritis who achieve only a partial response with adalimumab demonstrate a low risk for worsened symptoms and a high likelihood of meaningful improvement when switching to sarilumab, according to data.
TNF inhibitors ‘not always’ standard of care in spondyloarthritis
SCOTTSDALE, Ariz. — Although TNF inhibitors can work “across the spectrum” in spondyloarthritis, they are “not always” the standard of care, according to a presenter at the Basic and Clinical Immunology for the Busy Clinician symposium.
Patients’ priorities, individual burden should guide psoriatic arthritis treatment
SCOTTSDALE, Ariz. — Understanding patients’ disease burden and priorities can help rheumatologists choose the best therapy for psoriatic arthritis, noted a speaker at the Basic and Clinical Immunology for the Busy Clinician symposium.
Guselkumab’s safety profile consistent regardless of TNF-inhibitor use in psoriatic arthritis
The 2-year safety profile of guselkumab appears consistently favorable across patients with psoriatic arthritis who are either naïve or experienced with TNF inhibitors, according to data published by The Journal of Rheumatology.
Ustekinumab, TNF inhibitors exhibit comparable 3-year persistence in psoriatic arthritis
Ustekinumab and TNF inhibitors demonstrate comparably persistent effects at 3 years in patients with psoriatic arthritis, but with fewer adverse events in those receiving ustekinumab, according to data.
Adding TNF inhibitor, triple therapy to RA treatment improves vascular inflammation
In patients with active rheumatoid arthritis despite methotrexate use, adding either a TNF inhibitor or triple therapy with sulfasalazine and hydroxychloroquine improves vascular inflammation, according to data.